PMID- 38378130 OWN - NLM STAT- Publisher LR - 20240228 IS - 1876-4738 (Electronic) IS - 0914-5087 (Linking) DP - 2024 Feb 18 TI - Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial. LID - S0914-5087(24)00020-0 [pii] LID - 10.1016/j.jjcc.2024.02.002 [doi] AB - BACKGROUND: We hypothesized that the beneficial effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on diastolic function might depend on baseline left ventricular (LV) systolic function. METHODS: To investigate the effects of SGLT2 inhibitors on LV diastolic function in patients with type 2 diabetes mellitus (T2DM), we conducted a post-hoc sub-study of the PROTECT trial, stratifying the data according to LV ejection fraction (LVEF) at baseline. After excluding patients without echocardiographic data at baseline or 24 months into the PROTECT trial, 31 and 38 patients with T2DM from the full analysis dataset of the PROTECT trial who received ipragliflozin or no SGLT2 inhibitor (control), respectively, were included. The primary endpoint was a comparison of the changes in echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels from baseline to 24 months between the two groups stratified according to baseline LVEF. RESULTS: Differences in diastolic functional parameters (e' and E/e') were noted between the two groups. Among the subgroups defined according to median LVEF values, those with higher LVEF (>/=60 %) who received ipragliflozin appeared to have a higher e' and lower E/e' than did those who received the standard of care with no SGLT2 inhibitor, indicating longitudinal improvements between baseline and follow up (p = 0.001 and 0.016, respectively). CONCLUSIONS: Ipragliflozin generally improved LV diastolic function in patients with type 2 diabetes, the extent of this improvement might appear to vary with LV systolic function. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Kusunose, Kenya AU - Kusunose K AD - Department of Cardiovascular Medicine, Nephrology, and Neurology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Electronic address: kusunok@med.u-ryukyu.ac.jp. FAU - Imai, Takumi AU - Imai T AD - Clinical and Translational Research Center, Kobe University Hospital, Kobe, Japan. FAU - Tanaka, Atsushi AU - Tanaka A AD - Department of Cardiovascular Medicine, Saga University, Saga, Japan. FAU - Doi, Masaru AU - Doi M AD - Doi Internal Medical Clinic, Kumamoto, Japan. FAU - Koide, Yuji AU - Koide Y AD - Department of Cardiovascular Medicine, Nagasaki University Hospital, Nagasaki, Japan. FAU - Fukumoto, Kazuo AU - Fukumoto K AD - Department of Medical Education and General Practice, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Kadokami, Toshiaki AU - Kadokami T AD - Department of Cardiovascular Medicine, Saiseikai Futsukaichi Hospital, Chikushino, Japan. FAU - Ohishi, Mitsuru AU - Ohishi M AD - Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Teragawa, Hiroki AU - Teragawa H AD - Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan. FAU - Ohte, Nobuyuki AU - Ohte N AD - Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. FAU - Yamada, Hirotsugu AU - Yamada H AD - Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. FAU - Sata, Masataka AU - Sata M AD - Department of Cardiovascular Medicine, Tokushima University Hospital, Tokushima, Japan. FAU - Node, Koichi AU - Node K AD - Department of Cardiovascular Medicine, Saga University, Saga, Japan. CN - PROTECT investigators LA - eng PT - Journal Article DEP - 20240218 PL - Netherlands TA - J Cardiol JT - Journal of cardiology JID - 8804703 SB - IM OTO - NOTNLM OT - Diastolic function OT - Echocardiography OT - Ipragliflozin OT - N-terminal pro-brain natriuretic peptide OT - Type 2 diabetes mellitus COIS- Declaration of competing interest TI received lecture fees from JCR Pharmaceuticals and KyowaKirin; and outsourcing fees from Organization for Clinical Medicine Promotion. AT received honoraria from Boehringer Ingelheim Japan and research funding from GlaxoSmithKline, Takeda, Bristol-Myers Squibb, and Novo Nordisk. HT received honoraria from Abbott Medical Japan, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Ono, Mitsubishi Tanabe, and Takeda. MS received grants and personal fees from Mitsubishi Tanabe, Takeda, Daiichi Sankyo, Astellas, Pfizer, Novartis, Boehringer Ingelheim, Bayer, MSD, Kowa, and AstraZeneca. NK has received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka, Takeda Pharmaceutical; Research grants from Asahi Kasei, Astellas, Boehringer Ingelheim Japan, Fuji Yakuhin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Novartis Pharma, Teijin Pharma; Scholarships from Bayer Yakuhin, Medtronic, Teijin Pharma. All other authors declare no competing interests. AT and KN are Editorial Board members of Cardiovascular Diabetology and were not involved in handling this manuscript during the submission and the review processes. EDAT- 2024/02/21 11:14 MHDA- 2024/02/21 11:14 CRDT- 2024/02/20 19:12 PHST- 2023/12/03 00:00 [received] PHST- 2024/02/07 00:00 [revised] PHST- 2024/02/12 00:00 [accepted] PHST- 2024/02/21 11:14 [pubmed] PHST- 2024/02/21 11:14 [medline] PHST- 2024/02/20 19:12 [entrez] AID - S0914-5087(24)00020-0 [pii] AID - 10.1016/j.jjcc.2024.02.002 [doi] PST - aheadofprint SO - J Cardiol. 2024 Feb 18:S0914-5087(24)00020-0. doi: 10.1016/j.jjcc.2024.02.002.